# Kingworld Medicines Group (01110.HK) Signs MOU to Pursue Exclusive Distribution Rights for Two Lingnan Formula Products

- Link: https://www.thailand-business-news.com/pr-news/kingworld-medicines-group-01110-hk-signs-mou-to-pursue-exclusive-distribution-rights-for-two-lingnan-formula-products
- Published: 2026-06-15T12:08:00+07:00
- Author: PR Newswire

**Targeting Full-Channel Sales Coverage in Hong Kong, Mainland China and Cross-border
E-commerce **

HONG KONG, June 15, 2026 /PRNewswire/ — Kingworld Medicines Group Limited ("Kingworld
Medicines" or the "Group", Stock Code: 01110.HK) announced that Morning Gold Medicine
Company Limited ("Morning Gold"), a connected person of the Group, has entered into
a memoranda of understanding (the "R&D MOUs") with Dongguan City Chinese Medicine
Hospital of Guangzhou University of Chinese Medicine ("Dongguan City Chinese Medicine
Hospital") in relation to the research and development ("R&D") cooperation of the
products "Zizhu Leaf Cleansing Solution" and "Modified Gastrodia Brain-Health Formula"(
collectively, the "Products"). The parties intend to collaborate closely on the 
R&D of the Products, including clinical research, regulatory registration and commercialisation.
At the same time, Morning Gold has also entered into separate memoranda of understanding(
the "Distribution MOUs") with the Group, pursuant to which Morning Gold intends 
to appoint the Group as the sole and exclusive distributor of the Products, covering
Hong Kong, Mainland China and cross-border e-commerce channels.

"Zizhu Leaf Cleansing Solution" is a Lingnan formula that has been used within Dongguan
City Chinese Medicine Hospital and in respect of which clinical observation data
and application experience have been accumulated over time. The product has been
applied in cases involving skin burns, diabetic foot ulcers and pressure sores. "
Modified Gastrodia Brain-Health Formula" was developed with reference to Gastrodia
Brain-Health Granules, which are currently used within Dongguan City Chinese Medicine
Hospital for symptoms associated with upward disturbance of wind-phlegm, including
dizziness, headache, memory impairment and insomnia.

As a connected party and important customer of the Group, Morning Gold has preliminarily
agreed commercial cooperation terms with Dongguan City Chinese Medicine Hospital.
In the initial phase, each Product is expected to be registered in Hong Kong as 
an HKC category proprietary Chinese medicine by a subsidiary of Morning Gold. Upon
obtaining approval, Morning Gold will organise production and, together with Dongguan
City Chinese Medicine Hospital, commence commercialisation. The Distribution MOUs
entered into simultaneously between Morning Gold and the Group indicate that Morning
Gold intends to appoint the Group as the sole and exclusive distributor of the two
Products across all channels, including retail, hospital and online platforms. Morning
Gold has agreed that, during the term of the Distribution MOUs and the definitive
agreements, it will not appoint any third-party distributors for the distribution
of the Products within the agreed scope. The Group will be responsible for overall
marketing, distribution network development and sales of the Products, while Morning
Gold will ensure compliant production, stable supply and provision of necessary 
product documentation and support. Distribution is expected to commence first in
Hong Kong and cross-border channels, followed by expansion into Mainland China upon
obtaining the national drug registration approval.

Mr. Zhao Lisheng, Chairman of Kingworld Medicines, said: "This collaboration marks
a significant breakthrough in the Group’s strategic positioning within the healthcare
sector—from our traditional role as a sole agent and distributor to proactively 
sourcing high-quality products at their origin. The Products are developed from 
years of clinical practice at Dongguan City Chinese Medicine Hospital, with proven
efficacy and well-established applications, providing a solid foundation for market
adoption.

The Group has been granted exclusive distribution rights for the Products across
Hong Kong, Mainland China, and cross-border e-commerce channels. This not only directly
enriches our healthcare product portfolio but also creates strong synergies with
our existing distribution network and channel resources, fully leveraging the channel
capabilities and market influence we have built over three decades in the healthcare
industry."

Mr. Zhao added, "Dongguan City Chinese Medicine Hospital has a number of national
key specialties and high-level medical centers, as well as professional research
platforms. It has long been dedicated to the R&D, and clinical translation, of in-
hospital specialty Chinese medicine preparations. Morning Gold has wholly owned 
proprietary Chinese medicine manufacturing enterprises in both Shenzhen and Hong
Kong that comply with GMP standards, and focuses on the research, development and
production of high-quality proprietary Chinese medicines. Leveraging this collaboration
as a model, we will continue to extend upstream to source high-quality products 
with strong clinical validation, introducing more effective and widely recognized
healthcare products. At the same time, we will accelerate the development of our
omni-channel commercialization strategy to drive sustainable business growth for
the Group."

– Ends –

**About Kingworld Medicines Group (Stock Code: 01110.HK) **

Kingworld Medicines Group (Stock Code: 01110.HK) has been committed to building 
a comprehensive upstream and downstream supply chain system for the pharmaceutical
and healthcare industry for over 30 years, with its business footprint currently
covering 34 provinces and municipalities across China, and has built a full-channel
integrated healthcare service system. Through Shenzhen Kingworld Medicines, the 
Group is principally engaged in the agency distribution of branded imported pharmaceutical
and healthcare products in China, representing a wide range of renowned healthcare
brands, including Nin Jiom Pei Pa Koa, Seirogan and Kingworld Imada Red Flower Oil.
The Group has established a leading position in the industry as a branded pharmaceutical
and healthcare products distributor. For more information, please visit [https://www.kingworld.com.cn/](https://www.kingworld.com.cn/).

**About Morning Gold Medicine Company Limited**

Morning Gold Medicine Company Limited was incorporated in Hong Kong in 1999. The
company wholly owns proprietary Chinese medicine manufacturing enterprises in both
Shenzhen and Hong Kong that comply with GMP standards, and focuses on the research,
development and production of high-quality proprietary Chinese medicines.

**About Dongguan City Chinese Medicine Hospital of Guangzhou University of Chinese
Medicine**

Founded in 1965, Dongguan City Chinese Medicine Hospital is a Grade 3A modern Chinese
medicine hospital integrating medical services, teaching, research, rehabilitation,
and preventive healthcare. In terms of disciplines and research, the hospital has
established two national key specialties, four national advantageous specialties
in Chinese medicine, and a number of provincial and municipal key specialties. It
has also successfully developed a number of high-level clinical medical centers,
including the China Chest Pain Center, the National Advanced Stroke Center, and 
the Guangdong Provincial Grade III Trauma Center. Dongguan City Chinese Medicine
Hospital also actively leverages university-government co-development resources 
to advance the development of a high-level research-oriented hospital. It has established
the Dongguan Traditional Chinese Medicine Center, the Dongguan Orthopedics and Traumatology
Research Center, and the Guangdong-Hong Kong-Macao Greater Bay Area Chinese Medicine
Engineering Technology Research Institute. Its project "Construction of a 5G-based
Regional Chinese Medicine Service System" was selected as a national pilot project
for 5G + medical and healthcare applications, and its Orthopedics and Traumatology
Research Center has been included in the national key hospital project for distinctive
Chinese medicine specialties.

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Kingworld Medicines Group (01110.HK) Signs MOU to Pursue Exclusive Distribution Rights for Two Lingnan Formula Products ](http://www.prnasia.com/story/archive/4981728_AE81728_0?rand=184833)
